SLS SELLAS Life Sciences Group Inc
Price (delayed)
$1.09
Market cap
$99.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$86.04M
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from
Highlights
SLS's EPS has surged by 63% year-on-year and by 28% since the previous quarter
SELLAS Life Sciences Group's net income has increased by 17% YoY and by 4.3% QoQ
SELLAS Life Sciences Group's debt has surged by 74% QoQ and by 10% YoY
SELLAS Life Sciences Group's equity has decreased by 40% from the previous quarter
Key stats
What are the main financial stats of SLS
Market
Valuations
Earnings
Shares outstanding
90.85M
Market cap
$99.02M
Enterprise value
$86.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$31.51M
Net income
-$30.88M
EBIT
-$30.88M
EBITDA
-$30.32M
Free cash flow
-$35.4M
Per share
Balance sheet
Liquidity
EPS
-$0.5
EPS diluted
-$0.5
Free cash flow per share
-$0.58
Book value per share
$0.13
Revenue per share
$0
TBVPS
$0.29
Total assets
$19.43M
Total liabilities
$9.97M
Debt
$1M
Equity
$9.47M
Working capital
$6.82M
Debt to equity
0.11
Current ratio
1.72
Quick ratio
1.47
Net debt/EBITDA
0.43
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-144.5%
Return on equity
-325.5%
Return on invested capital
N/A
Return on capital employed
-311.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLS stock price
How has the SELLAS Life Sciences Group stock price performed over time
Intraday
0%
1 week
-7.63%
1 month
-7.63%
1 year
-7.63%
YTD
4.81%
QTD
0.93%
Financial performance
How have SELLAS Life Sciences Group's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.51M
Net income
-$30.88M
Gross margin
N/A
Net margin
N/A
SELLAS Life Sciences Group's net income has increased by 17% YoY and by 4.3% QoQ
The operating income has grown by 17% YoY and by 3.8% from the previous quarter
Growth
What is SELLAS Life Sciences Group's growth rate over time
Valuation
What is SELLAS Life Sciences Group stock price valuation
P/E
N/A
P/B
8.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SLS's EPS has surged by 63% year-on-year and by 28% since the previous quarter
SELLAS Life Sciences Group's equity has decreased by 40% from the previous quarter
SLS's price to book (P/B) is 23% lower than its last 4 quarters average of 10.6 but 10% higher than its 5-year quarterly average of 7.4
Efficiency
How efficient is SELLAS Life Sciences Group business performance
The company's return on equity has surged by 86% YoY and by 48% QoQ
SELLAS Life Sciences Group's return on assets has increased by 40% YoY and by 19% QoQ
Dividends
What is SLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLS.
Financial health
How did SELLAS Life Sciences Group financials performed over time
The total assets is 95% greater than the total liabilities
SLS's total liabilities is down by 30% YoY and by 6% QoQ
The total assets has declined by 27% since the previous quarter
SELLAS Life Sciences Group's debt is 89% lower than its equity
The debt to equity has soared by 200% YoY and by 175% from the previous quarter
SELLAS Life Sciences Group's debt has surged by 74% QoQ and by 10% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.